Abstract: Objective: To investigate the correlation of p53codon 72polymorphism with clinicopathologic features of breast cancer patients including age, tumor staging, lymph node status, receptor status of estrogen and progestin, expres-sion of P 53protein and c-erbB- 2. Methods:Blood samples were collected from 277 women with primary breast cancer. Taq-Man was used to determine the genotypes of p53codon 72polymorphism. Expression of ER, PR, c-erbB- 2 and P 53pro-teins were detected with immunohistochemistry. SPSS 16.0 software was employed for statistical analysis and the relation -ship of p 53polymorphism with all of the clinicopathologic parameters was evaluated with χ2 test. Furthermore, the associa -tion of p 53polymorphism with ER, PR, c-erbB- 2 and P 53protein expression was analyzed by logistic regression analysis. Results: The frequency of CC, CG, and GG at p 53codon 72was 22.0%,51.3%, and26.7%, respectively. No correlation was found between genotype distribution and clinicopathologic parameters of disease outcome. There was no correlation between p 53condon 72polymorphisms and the expression of ER, PR, c-erbB-2, or P 53proteins (P>0.05). P 53protein ex-pression was associated with expression of ER, PR, and c-erbB-2 proteins (χ2=13.492 , P=0.000 ; χ2=3.970 , P=0.046 ; χ2=17.956 , P=0.000 ). Conclusion:There is no correlation between p53codon 72polymorphism and clinicopathologic parame -ters of breast cancer. P 53protein is significantly associated with ER, PR and c-erbB-2 expression. Further study using a larger sample is warranted.